Literature DB >> 26958148

Preserved Visual Acuity in Anterior Ischemic Optic Neuropathy Secondary to Giant Cell (temporal) Arteritis.

Aileen A Antonio-Santos, Sally J Murad-Kejbou, Rod Foroozan, Sunita Yedavally, David I Kaufman, Eric R Eggenberger.   

Abstract

OBJECTIVE: To evaluate the prevalence and clinical profile of patients with biopsy-proven arteritic anterior ischemic optic neuropathy presenting with preserved visual acuity of 20/40 or better and those with an initial poor visual acuity of 20/50 or worse through a retrospective chart review.
RESULTS: Nine of 37 patients with arteritic anterior ischemic optic neuropathy presented with a preserved visual acuity of 20/40 or better in the affected eye. All patients with preserved visual acuity had initial visual field defects that spared the central field. All 37 patients immediately received high-dose corticosteroid therapy. Visual acuity worsened by > 2 lines in one of nine patients (11%) with preserved visual acuity, with a corresponding progression of visual field constriction.
CONCLUSION: Although preserved visual acuity of 20/40 or better has traditionally been associated with the nonarteritic form of anterior ischemic optic neuropathy, giant cell arteritis should still be strongly considered, especially if they have giant cell arteritis systemic symptoms.

Entities:  

Year:  2016        PMID: 26958148      PMCID: PMC4762406     

Source DB:  PubMed          Journal:  J Vasc Interv Neurol        ISSN: 1941-5893


  9 in total

1.  Ocular manifestations of giant cell arteritis.

Authors:  S S Hayreh; P A Podhajsky; B Zimmerman
Journal:  Am J Ophthalmol       Date:  1998-04       Impact factor: 5.258

Review 2.  Giant cell (temporal) arteritis.

Authors:  G G Hunder
Journal:  Rheum Dis Clin North Am       Date:  1990-05       Impact factor: 2.670

3.  Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis.

Authors:  C Font; M C Cid; B Coll-Vinent; A López-Soto; J M Grau
Journal:  Br J Rheumatol       Date:  1997-02

Review 4.  Recovery of visual function in patients with biopsy-proven giant cell arteritis.

Authors:  Rod Foroozan; Vincent A Deramo; Lawrence M Buono; D Gerard R Jayamanne; Robert C Sergott; Helen Danesh-Meyer; Peter J Savino
Journal:  Ophthalmology       Date:  2003-03       Impact factor: 12.079

5.  Poor prognosis of visual outcome after visual loss from giant cell arteritis.

Authors:  Helen Danesh-Meyer; Peter J Savino; Greg G Gamble
Journal:  Ophthalmology       Date:  2005-06       Impact factor: 12.079

Review 6.  Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone.

Authors:  W T Cornblath; E R Eggenberger
Journal:  Ophthalmology       Date:  1997-05       Impact factor: 12.079

Review 7.  Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy.

Authors:  Sohan Singh Hayreh; Bridget Zimmerman
Journal:  Ophthalmology       Date:  2003-06       Impact factor: 12.079

8.  Risk factors for early visual deterioration in temporal arteritis.

Authors:  Tobias Loddenkemper; Pankaj Sharma; I Katzan; Gordon T Plant
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05-15       Impact factor: 10.154

Review 9.  Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature.

Authors:  Sohan Singh Hayreh; Bridget Zimmerman; Randy H Kardon
Journal:  Acta Ophthalmol Scand       Date:  2002-08
  9 in total
  1 in total

1.  Giant Cell Arteritis: The Experience of Two Collaborative Referral Centers and an Overview of Disease Pathogenesis and Therapeutic Advancements.

Authors:  Rosanna Dammacco; Giovanni Alessio; Ermete Giancipoli; Patrizia Leone; Anna Cirulli; Leonardo Resta; Angelo Vacca; Franco Dammacco
Journal:  Clin Ophthalmol       Date:  2020-03-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.